Suchergebnisse - "O'Connor, Owen A"

PubPharm (52)

1

Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance

enthalten in: BMC cancer | 2021

von Oiwa, K. | Hosono, N. | Nishi, R. | +3

2

Generation of pralatrexate resistant T-cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers

enthalten in: Genes, chromosomes & cancer | 2020

von Scotto, L. | Kinahan, C. | Casadei, B. | +9

3

The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management

enthalten in: CA: a cancer journal for clinicians | 2020

von Marchi, E. | O'Connor, O.

4

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2019

von Kahl, B. | Hamadani, M. | Radford, J. | +12

5

Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model

enthalten in: Cell chemical biology | 2019

von Zhang, Y. | Tan, H. | Daniels, J. | +6

CommentIn: Cell Chem Biol. 2019 May 16;26(5):621-622. - PMID 31100261

6

New directions in treating peripheral T-cell lymphomas (PTCL) : leveraging epigenetic modifiers alone and in combination

enthalten in: Expert review of hematology | 2019

von Ma, H. | O'Connor, O. | Marchi, E.

7

Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2019

von O'Connor, O. | Özcan, M. | Jacobsen, E. | +27

8

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial

enthalten in: Lancet (London, England) | 2019

von Horwitz, S. | O'Connor, O. | Pro, B. | +129

CommentIn: Lancet. 2019 Jan 19;393(10168):201-202. - PMID 30663580

9

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma : an open-label, phase 1, dose-escalation, first-in-human study

enthalten in: The Lancet. Oncology | 2018

von Burris, H. | Flinn, I. | Patel, M. | +12

CommentIn: Lancet Oncol. 2018 Apr;19(4):432-434. - PMID 29475725

10

A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab

enthalten in: British journal of haematology | 2017

von Sawas, A. | Farber, C. | Schreeder, M. | +10

1
2
3
4
5
6
Nächster »
[6]